In December, the FDA declared that shortages of treatments Zepbound and Mounjaro from another drugmaker, Eli Lilly and Co., ...

The FDA said the shortage of Novo Nordisk's weight-loss drugs Wegovy and Ozempic is resolved. The move could limit cheaper compounded versions ...

Now, one type of weight-loss medication is proving helpful with another health issue. In a study published Feb. 12 in JAMA ...

Research links weight loss medications like Ozempic and Zepbound to certain serious eye conditions.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial of its experimental drug CagriSema — a combination of semaglutide and a ...

The FDA declared the end of the shortage of Novo Nordisk’s Wegovy and Ozempic, impacting compounding pharmacies selling ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ingredient, they are approved for different purposes. Ozempic is primarily ...

Ozempic and Wegovy, the popular GLP-1 drugs for diabetes and weight loss, are no longer in short supply, the FDA declared ...

Cost is a major obstacle for many. The drugs can be expensive without insurance, with out-of-pocket expenses reaching hundreds of dollars per prescription. The poll found that about half of Americans ...

Utah’s Attorney General Derek Brown signed onto a letter along with attorneys general from 37 other states to ask the Food and Drug Administration to enforce the safety of weight loss drugs.

Ozempic is primarily used for managing type ... though it’s not a weight loss medication. Starting dose: 0.25 mg weekly for 4 weeks. Gradually increased to a maximum dose of 2.0 mg weekly.